Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 119

Results For "therapy"

1752 News Found

JB Pharma to buy Glenmark's ‘Razel’ for Rs. 314 crore in India and Nepal
News | December 14, 2022

JB Pharma to buy Glenmark's ‘Razel’ for Rs. 314 crore in India and Nepal

The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy


Evonik invests in US based biopharma company ‘Allay Therapeutics’
News | December 13, 2022

Evonik invests in US based biopharma company ‘Allay Therapeutics’

Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks


Moderna and Merck announce personalized mRNA cancer vaccine
Clinical Trials | December 13, 2022

Moderna and Merck announce personalized mRNA cancer vaccine

Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial


Inclusion of Yoga in the treatment of breast cancer patients is highly beneficial
News | December 13, 2022

Inclusion of Yoga in the treatment of breast cancer patients is highly beneficial

The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama


Fraunhofer IZI Selects Lonza’s MODA-ES Solution to Digitalize Manufacturing Operations
News | December 07, 2022

Fraunhofer IZI Selects Lonza’s MODA-ES Solution to Digitalize Manufacturing Operations

GMP-compliant documentation of all manufacturing steps for cell and gene therapies


ASG Eye Hospitals opens hospital in Vashi
Healthcare | December 06, 2022

ASG Eye Hospitals opens hospital in Vashi

The new eye hospital in Vashi is ASG’s second in the Mumbai Metropolitan Region (MMR) and the sixth in Maharashtra


Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study
News | December 05, 2022

Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study

Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer


Merck to present data from Its hematology portfolio ASH meeting
News | December 05, 2022

Merck to present data from Its hematology portfolio ASH meeting

Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers


Jemperli RUBY phase III trial met its primary endpoint
Clinical Trials | December 05, 2022

Jemperli RUBY phase III trial met its primary endpoint

Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival